NCT07359859

A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant

Randomized Pilot Study of Ruxolitinib for Switch-Maintenance Prophylaxis of Graft-versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation After Intermediate-Dose Post-Transplant Cyclophosphamide (Rux Switch-Maintenance in Intermediate PTCY: RuSMa-PTCY) in Comparison to Full-Dose PTCY

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The researchers are doing this study to compare 2 different GVHD prevention (prophylaxis) approaches. The researchers will see which approach is good or more effective at preventing chronic GVHD until 1 year after allogeneic hematopoietic stem cell transplantation (allo-HCT).

Conditions

• Hematologic Malignancies

Interventions

Type	Name	Description
DRUG	Cyclophosphamide	An intermediate dose (medium dose) of Post-transplant Cyclophosphamide
DRUG	Cyclophosphamide	A full dose of Post-transplant Cyclophosphamide
DRUG	Mycophenolate Mofetil	Day +5 to +35
DRUG	Ruxolitinib	twice a day
DRUG	Tacrolimus	Day +5, taper per SoC
DRUG	Tacrolimus	Day +5, taper initiation within 2 weeks of starting Ruxolitinib

Timeline

• Start date: 2026-01-20
• Primary completion: 2029-01-01
• Completion: 2029-01-01
• First posted: 2026-01-22
• Last updated: 2026-02-17

Locations

7 sites across 1 country: United States

Regulatory

• FDA-regulated drug study